Biomedical Engineering Reference
In-Depth Information
antibodies: application to anti-respiratory syncytial virus Mab. Anal Chem 1995;67:3613-
3625.
[9] Bigge JC, Patel TP, Bruce JA, Goulding PN, Charles SM, Parekh RB. Nonselective and
efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. Anal
Biochem 1995;230:229-238.
[10] Guile GR, Rudd PM, Wing DR, Prime SB, Dwek RA. A rapid high-resolution
high-performance liquid chromatographic method for separating glycan mixtures and
analyzing oligosaccharide profiles. Anal Biochem 1996;240:210-226.
[11] Galili U. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in
cancer immunotherapy. Immunol Cell Biol 2005;83:674-686.
[12] Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM,
Hosen J, Mauro D, Slebos RJ, Zhour Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA.
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl
J Med 2008;358:1109-1117.
[13] Jones AJS, Papac DI, Chin EH, Keck R, Baughman SA, Lin YS, Kneer J, Battersby JE.
Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by
terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology
2007;17:529-540.
[14] Prime S, Merry T. Exoglycosidase sequencing of N-linked glycans by the reagent array
analysis methods (RAAM). In: Hounsell EF, editor. Methods in Molecular, Biology:
Glycoanalysis Protocols. Humana Press; 1998. p 53-69.
[15] Spiro RG, Study of the carbohydrates of glycoproteins. Methods Enzymol 1972;28:3-43.
[16] Mage MG, Preparation of Fab fragments from IgGs of different animal species. Methods
Enzymol 1980; 70: 142-150.
[17] Rousseaux J, Rousseaux-Prevost R, Bazin H. Optimal conditions for the preparation of
proteolytic fragments from monoclonal IgG of different rat IgG subclasses. Methods
Enzymol 1986;121:663-669.
[18] Wu H, Pfarr DS, Tang Y, An L-L, Patel NK, Watkins JD, HuseWD, Kiener PA, Young JF.
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and
binding valence on viral neutralization. J Mol Biol 2005;350:126-144.
[19] Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related
receptor FcRn. Annu Rev Immunol 2000;18:739-766.
[20] Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of
respiratory syncytial virus infection in cotton rats. Am J Pathol 1978;93:771-791.
[21] Byrd LG, Prince GA. Animal models of respiratory syncytial virus infection. Clin Infect Dis
1997;25:1363-1368.
[22] PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among
premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial
virus immune globulin prophylaxis. Pediatrics 1997;99:93-99.
[23] IMPACT-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclo-
nal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk
infants. Pediatrics 1998;102:531-537.
[24] PrinceGA, HemmingVG, HorswoodRL, BaronPA, MurphyBR, ChanockRM. Mechanism
of antibody-mediatedviral clearance in immunotherapy of respiratory syncytial virus infection
of cotton rats. J Virol 1990;64:3091-3092.
Search WWH ::




Custom Search